The safety profile of moxifloxacin and other fluoroquinolones in special patient populations

@article{Iannini2007TheSP,
  title={The safety profile of moxifloxacin and other fluoroquinolones in special patient populations},
  author={Paul B. Iannini},
  journal={Current Medical Research and Opinion},
  year={2007},
  volume={23},
  pages={1403 - 1413}
}
  • P. Iannini
  • Published 8 May 2007
  • Medicine, Biology
  • Current Medical Research and Opinion
ABSTRACT Background: Fluoroquinolones, including ciprofloxacin, levofloxacin, gemifloxacin, and moxifloxacin, represent a major advance in the development of antimicrobial agents. They offer significant activity against Gram-negative pathogens, while more advanced generation fluoroquinolones including levofloxacin, gemifloxacin, and moxifloxacin are significantly active against Gram-positive (e.g., Streptococcus pneumoniae for some members of the class), typical, atypical, and anaerobic… 
Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin
TLDR
The data show that using moxifloxacin, in its accepted indications and following the corresponding guidelines, should not be associated with an excessive incidence of drug-related adverse reactions, provided the clinician takes care in identifying patients with known risk factors and pays due attention to the contraindications and warnings mentioned in the labelling.
Safety Considerations of Fluoroquinolones in the Elderly
TLDR
Overall, the specific adverse-effect profile of quinolones must be considered when they are chosen for treatment of bacterial infections because of physiological changes in renal function and when certain co-morbidities are present, some special considerations are necessary when elderly patients are treated with these drugs.
Fluoroquinolones in the management of community-acquired pneumonia in primary care
TLDR
Review of the pharmacokinetic and pharmacodynamic profile of the respiratory fluoroquinolones suggested that moxifloxacin and gemiflOxacin are more potent against S. pneumoniae, which may have the added benefit of reducing resistance selection and enhancing bacterial eradication.
Moxifloxacin Safety
TLDR
The safety of moxifloxacin is essentially comparable to that of standard therapies for patients receiving the currently registered dosage and for whom contraindications and precautions of use (as in the product label) are taken into account.
An Analysis of 14 Years of Clinical Data
TLDR
The safety profile of moxifloxacin versus comparators in the entire clinical database of the manufacturer was analyzed and fatal outcomes related to an AE or ADR were identified.
Comparing therapeutic and adverse effects of moxifloxacin and levofloxacin in treatment of community acquired pneumonia: A meta-analysis of randomized controlled trials
TLDR
Moxifloxacin has better therapeutic effects with comparable adverse events compared to levofloxACin, and lev ofloxAcin monotherapy was associated with better therapeutic effect and similar adverse effect compared with levofLoxacIn therapy for CAP.
Efficacy and Safety of Nadifloxacin for Bacterial Skin Infections: Results from Clinical and Post-Marketing Studies
TLDR
Nadifloxacin, a fluoroquinolone, is a new alternative topical agent in the treatment of bacterial skin infection with minimal AEs.
Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials
TLDR
It is found that moxifloxacin is as effective and well-tolerated as other recommended antibiotics for the treatment of CAP and possesses a better pathogen eradication rate than beta-lactam-based therapy.
The Risk of Hepatotoxicity with Fluoroquinolones : A National Case-Control Safety Study
TLDR
Assessment of the risk of hepatotoxicity in patients using fluoroquinolones compared to non-users found a statistically significant increased risk of liver damage, but not with ciprofloxacin use individually, and this was not associated with levofloxacins or moxifloxAcin use.
Miscellaneous antibacterial drugs
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 77 REFERENCES
A Critical Review of the Fluoroquinolones
TLDR
The new fluoroquinolones offer several advantages over ciprofloxacin and are emerging as important therapeutic agents in the treatment of community-acquired respiratory infections, and may be used orally in place of intravenous antibacterials.
A critical review of the fluoroquinolones: focus on respiratory infections.
TLDR
Limited data suggest that the new fluoroquinolones as a class may lead to better outcomes in community-acquired pneumonia and acute exacerbations of chronic bronchitis versus comparators.
Clinical use of the fluoroquinolones.
Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract.
TLDR
The broad-spectrum antimicrobial activity, tissue distribution and safety profile of fluoroquinolones suggest that they have a place in respiratory tract infection.
Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors
TLDR
Once-daily oral moxifloxacin alone is as effective as amoxicillin-clavulanate plus roxithromycin for the treatment of CAP in patients with risk factors, and the intent-to-treat analysis confirmed these results.
Retrospective Analysis of the Safety Profile of Oral Moxifloxacin in Elderly Patients Enrolled in Clinical Trials
TLDR
A pooled analysis suggests that oral moxifloxacin can be safely used in elderly patients with characteristics consistent with those enrolled into the clinical trials.
Moxifloxacin penetration into human gastrointestinal tissues.
TLDR
Moxifloxacin penetrates into and accumulates in the mucosa of the stomach, small bowel and colon to evaluate its potential role as an antimicrobial drug in bacterial infections of the GI tract.
Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval
  • P. Iannini
  • Medicine, Biology
    Expert opinion on drug safety
  • 2002
TLDR
The overall risk of ventricular arrhythmias is very small with these agents but can be reduced further by avoiding their usage for patients with other multiple risk factors for Torsades de Pointes.
Clinical toxicological aspects of fluoroquinolones.
QT prolongation with antimicrobial agents: understanding the significance.
TLDR
It appears that in most published cases of antimicrobial-associated TdP, multiple risk factors are present, and a risk stratification scheme may be useful to rank and compare the potential for cardiotoxicity of each drug.
...
1
2
3
4
5
...